Primary Mediastinal Large B-Cell Lymphoma: Clinical Trials

11 trials for Primary Mediastinal Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 11 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 4, Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 14Active not recruiting 1, Completed 1, Terminated 1, Unknown 1

Follow Primary Mediastinal Large B-Cell Lymphoma: new trials by email Literature Review of Primary Mediastinal Large B-Cell Lymphoma trials Research Report on Primary Mediastinal Large B-Cell Lymphoma

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma
Phase 2RecruitingUniversity of Washington182025-12-072026-10-21
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Phase 2RecruitingMarcela V. Maus, M.D.,Ph.D.282024-09-182026-10-06
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma
Phase 2RecruitingAcademic and Community Cancer Research United1202024-01-312024-09-26
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma
Phase 1 / Phase 2Active not recruitingUniversity of Washington562020-10-272026-10-02
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2TerminatedGenmab462020-03-132024-10-24
Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs
Decitabine, GVD chemotherapy, SHR-1210 - Primary Mediastinal Large B-cell Lymphoma
Phase 1 / Phase 2UnknownChinese PLA General Hospital302017-05-012018-12-03
Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
MDV9300 - Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma
Phase 2WithdrawnMedivation, Inc.2016-12-012016-11-25
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Ruxolitinib - Relapsed or Refractory Hodgkin Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Phase 2CompletedSamsung Medical Center202013-11-152018-11-01
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Tazemetostat, Prednisolone - B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1)
Phase 1 / Phase 2CompletedEpizyme, Inc.4002013-06-132024-03-26
CT-011 MAb in DLBCL Patients Following ASCT
CT-011 - Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
Phase 2CompletedCureTech Ltd722007-10-012014-09-12
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)3481993-05-082025-06-22

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (9)  ·  Lymphoma, Follicular (3)  ·  Recurrence (3)  ·  Burkitt Lymphoma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Hodgkin Disease (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, Mantle-Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (10)  ·  Immune System Diseases (10)  ·  Immunoproliferative Disorders (10)  ·  Lymphatic Diseases (10)  ·  Lymphoma (10)  ·  Lymphoproliferative Disorders (10)  ·  Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Lymphoma, B-Cell (7)  ·  Lymphoma, Non-Hodgkin (7)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  DNA Virus Infections (2)  ·  Epstein-Barr Virus Infections (2)

Interventions

Cyclophosphamide (4)  ·  Biopsy (3)  ·  Doxorubicin (3)  ·  Etoposide (3)  ·  Prednisone (3)  ·  Rituximab (3)  ·  Magnetic Resonance Spectroscopy (2)  ·  Specimen Handling (2)  ·  deltacortene (2)  ·  Antibodies, Monoclonal (1)  ·  CT-P10 (1)  ·  Decitabine (1)  ·  Dexamethasone (1)  ·  Dioctyl Sulfosuccinic Acid (1)  ·  Emapalumab (1)

Sponsors

University of Washington (2)  ·  Academic and Community Cancer Research United (1)  ·  Chinese PLA General Hospital (1)  ·  CureTech Ltd (1)  ·  Epizyme, Inc. (1)  ·  Genmab (1)  ·  Marcela V. Maus, M.D.,Ph.D. (1)  ·  Medivation, Inc. (1)  ·  National Cancer Institute (NCI) (1)  ·  Samsung Medical Center (1)

Countries

United States (9)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  India (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Arnon Nagler, MD (1)  ·  Grzegorz S Nowakowski (1)  ·  Leo I Gordon, MD (1)  ·  Mark J Roschewski, M.D. (1)  ·  Matthew Frigault, MD (1)  ·  Mengyang Di, MD, PhD (1)  ·  Ryan Lynch (1)  ·  Won Seog Kim, PhD (1)

Results publications

PMID 23574119, PMID 24127452, PMID 24224624, PMID 25024303, PMID 29650362, PMID 29748435, PMID 30125215, PMID 31707975, PMID 33035457, PMID 34432874, PMID 35882475, PMID 36521030, PMID 37981564, PMID 39563886, PMID 40802906

NIH funding

2019 (1), P30CA015083 (1)